PAFSC’s 2nd Committee to Review 7th Biopharmaceutical RA Drug on Nov. 29

The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second Committee on Drugs will review seven products/indications, including UCB Japan’s rheumatoid arthritis (RA) treatment certolizumab pegol, on November 29. If approved, certolizumab pegol would be the seventh biopharmaceutical drug for RA...read more